Open AccessInfluence of combined antihypertensive therapy on plasmatic,vascular-thrombocytic hemostasis and lipid peroxidation in patientswith metabolic syndrome and arterial hypertension
Author(s) -
Наталья Краснова,
Э. А. Бушкова
Publication year - 2007
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2007-4-58-63
Subject(s) - enalapril , verapamil , medicine , lipid peroxidation , hemostasis , calcium channel blocker , angiotensin converting enzyme , endocrinology , blood pressure , cardiology , pharmacology , calcium , oxidative stress
The impact of antihypertensive therapy with the angiotensin-converting enzyme inhibitor enalapril (enap) and with enalapril in combination with the long-acting calcium channel blocker verapamil SR (isoptin SR) on changes of plasmatic, vascular-thrombocytic hemostasis and lipid peroxidation in patients with metabolic syndrome and arterial hypertension was studied. Combined therapy with enalapril and verapamil significantly reduces the fasting glucose and glycated hemoglobin concentrations, the aggregation activity of thrombocytes in the patient's blood, inhibits the lipid peroxidation, increases the level of high-density lipoprotein cholesterol, and decreases the coefficient of atherogenecity. Combined therapy with enalapril and verapamil SR can be recommended for treatment of arterial hypertension in patients with metabolic syndrome.